FDA notifications. Tibotec issues Dear Health Care Professional letter.
D000069454:Darunavir; D004345:Drug Industry; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D008099:Liver / Q000187:drug effects*; D013449:Sulfonamides / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D000069454:Darunavir